BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20354416)

  • 1. Lessons from practice: risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result in women aged 21 to 24.
    Moore G; Fetterman B; Cox JT; Poitras N; Lorey T; Kinney W; Castle PE
    J Low Genit Tract Dis; 2010 Apr; 14(2):97-102. PubMed ID: 20354416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
    Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S36-42. PubMed ID: 23519303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Triage for Atypical Squamous Cells of Undetermined Significance with Human Papillomavirus Testing in Cervical Cancer Screening in Japan.
    Fujiwara H; Suzuki M; Morisawa H; Sayama M; Kimura K
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):81-85. PubMed ID: 30678384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S56-63. PubMed ID: 23519306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cervical precancer and cancer in women aged 30 years and older with an HPV-negative low-grade squamous intraepithelial lesion screening result.
    Littell RD; Kinney W; Fetterman B; Cox JT; Shaber R; Poitras N; Lorey T; Castle PE
    J Low Genit Tract Dis; 2011 Jan; 15(1):54-9. PubMed ID: 21192178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LA; Myers O; Cuzick J; Wentzensen N; Kinney W; Castle PE; Wheeler CM;
    Obstet Gynecol; 2016 Dec; 128(6):1248-1257. PubMed ID: 27824767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
    Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
    Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S43-9. PubMed ID: 23519304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening properties of human papillomavirus testing for predicting cervical intraepithelial neoplasia in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion smears: a prospective study.
    Dane C; Batmaz G; Dane B; Cetin A
    Ann Diagn Pathol; 2009 Apr; 13(2):73-7. PubMed ID: 19302953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High risk HPV testing in the triage of repeat ASC-US and LSIL.
    Veijalainen O; Tuomisaari S; Luukkaala T; Mäenpää J
    Acta Obstet Gynecol Scand; 2015 Sep; 94(9):931-6. PubMed ID: 26053676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion triage in Korean women: Revisiting the 2012 American Society of Colposcopy and Cervical Pathology screening guidelines.
    Hyun JY; Min KJ; Yang SY; Lee JK; Hong JH
    Obstet Gynecol Sci; 2017 Jul; 60(4):357-361. PubMed ID: 28791267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand.
    Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Suprasert P; Siriaunkgul S
    Asian Pac J Cancer Prev; 2014; 15(24):10961-6. PubMed ID: 25605209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-grade squamous intraepithelial lesion/cannot exclude high-grade squamous intraepithelial lesion (LSIL-H) is a unique category of cytologic abnormality associated with distinctive HPV and histopathologic CIN 2+ detection rates.
    Barron S; Li Z; Austin RM; Zhao C
    Am J Clin Pathol; 2014 Feb; 141(2):239-46. PubMed ID: 24436272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.
    Demarco M; Lorey TS; Fetterman B; Cheung LC; Guido RS; Wentzensen N; Kinney WK; Poitras NE; Befano B; Castle PE; Schiffman M
    J Low Genit Tract Dis; 2017 Oct; 21(4):261-267. PubMed ID: 28953116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
    Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
    Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].
    Guo YL; You K; Geng L; Zhang XW; Shen XY; Yao YJ; Fan XH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):480-2. PubMed ID: 17068618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S64-8. PubMed ID: 23519307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.